STOCK TITAN

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags

Rigel Pharmaceuticals (Nasdaq: RIGL) has announced the granting of inducement awards under its Inducement Plan, as approved by the company's Compensation Committee. The grants, made in accordance with NASDAQ Listing Rule 5635(c)(4), consist of 23,350 stock options and restricted stock units awarded to seven non-executive employees.

These equity awards will vest over a four-year period with a one-year cliff vesting schedule. The grants serve as inducement material for employees entering into employment with Rigel, a biotechnology company founded in 1996 that focuses on developing therapies for hematologic disorders and cancer.

Rigel Pharmaceuticals (Nasdaq: RIGL) ha annunciato l'assegnazione di premi di incentivazione secondo il suo Piano di Incentivazione, approvato dal Comitato per la Remunerazione dell'azienda. I premi, concessi in conformità con la Regola di Quotazione NASDAQ 5635(c)(4), consistono in 23.350 opzioni su azioni e unità azionarie vincolate assegnate a sette dipendenti non esecutivi.

Questi premi azionari matureranno in un periodo di quattro anni con un programma di maturazione di un anno. I premi servono come incentivo per i dipendenti che entrano in servizio con Rigel, una azienda biotecnologica fondata nel 1996 che si concentra sullo sviluppo di terapie per disturbi ematologici e cancro.

Rigel Pharmaceuticals (Nasdaq: RIGL) ha anunciado la concesión de premios de incentivo bajo su Plan de Incentivo, aprobado por el Comité de Compensación de la empresa. Las concesiones, realizadas de acuerdo con la Regla de Cotización de NASDAQ 5635(c)(4), consisten en 23,350 opciones sobre acciones y unidades de acciones restringidas otorgadas a siete empleados no ejecutivos.

Estos premios en acciones se consolidarán durante un período de cuatro años con un calendario de consolidación de un año. Las concesiones sirven como material de incentivo para los empleados que ingresan a trabajar en Rigel, una empresa biotecnológica fundada en 1996 que se centra en el desarrollo de terapias para trastornos hematológicos y cáncer.

리겔 제약 (Nasdaq: RIGL)은 회사의 보상 위원회에서 승인한 유인 계획에 따라 유인 보상을 부여한다고 발표했습니다. NASDAQ 상장 규정 5635(c)(4)에 따라 이루어진 이 보상은 23,350개의 주식 옵션 및 제한 주식 단위로, 비상임 직원 7명에게 수여됩니다.

이 자산 보상은 4년 기간 동안 분할될 예정이며, 1년의 클리프 분할 일정이 있습니다. 이 보상은 1996년에 설립된 생명공학 회사 리겔에 입사하는 직원들을 위한 유인 자료로 사용됩니다. 리겔은 혈액 질환 및 암 치료제를 개발하는 데 중점을 두고 있습니다.

Rigel Pharmaceuticals (Nasdaq: RIGL) a annoncé l'octroi de primes d'incitation dans le cadre de son Plan d'Incitation, approuvé par le Comité de Rémunération de l'entreprise. Les attributions, effectuées conformément à la Règle de Cotation NASDAQ 5635(c)(4), consistent en 23 350 options d'achat d'actions et unités d'actions restreintes attribuées à sept employés non exécutifs.

Ces attributions d'équité seront acquises sur une période de quatre ans avec un calendrier d'acquisition d'un an. Les attributions servent de matériel d'incitation pour les employés entrant en fonction chez Rigel, une entreprise de biotechnologie fondée en 1996 qui se concentre sur le développement de thérapies pour les troubles hématologiques et le cancer.

Rigel Pharmaceuticals (Nasdaq: RIGL) hat die Gewährung von Anreizprämien im Rahmen seines Anreizplans bekannt gegeben, der vom Vergütungsausschuss des Unternehmens genehmigt wurde. Die Gewährungen, die gemäß der NASDAQ-Listing-Regel 5635(c)(4) erfolgen, bestehen aus 23.350 Aktienoptionen und eingeschränkten Aktieneinheiten, die an sieben nicht-executive Mitarbeiter vergeben werden.

Diese Aktienvergaben werden über einen vierjährigen Zeitraum mit einem einjährigen Cliff-Vesting-Zeitplan fällig. Die Gewährungen dienen als Anreizmaterial für Mitarbeiter, die bei Rigel, einem 1996 gegründeten Biotechnologieunternehmen, das sich auf die Entwicklung von Therapien für hämatologische Erkrankungen und Krebs konzentriert, in den Dienst treten.

Positive
  • None.
Negative
  • None.

SOUTH SAN FRANCISCO, Calif., April 4, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees' entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4). Specifically, Rigel granted 23,350 stock options and restricted stock units to seven non-executive employees vesting over four years with a one-year cliff.  

About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, its marketed products and pipeline of potential products, please visit www.rigel.com.

Contact for Investors & Media
Rigel Pharmaceuticals, Inc.
650.624.1232
ir@rigel.com

Rigel Pharmaceuticals Logo (PRNewsfoto/Rigel Pharmaceuticals, Inc.)

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/rigel-pharmaceuticals-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302420551.html

SOURCE Rigel Pharmaceuticals, Inc.

FAQ

What type of inducement grants did Rigel Pharmaceuticals (RIGL) announce in April 2025?

Rigel announced 23,350 stock options and restricted stock units granted to seven non-executive employees, vesting over four years with a one-year cliff.

How will the inducement grants for RIGL employees vest?

The grants will vest over a four-year period with a one-year cliff vesting schedule.

How many employees received inducement grants from Rigel Pharmaceuticals in April 2025?

Seven non-executive employees received inducement grants from Rigel Pharmaceuticals.

Under which NASDAQ rule were Rigel's inducement grants approved?

The grants were approved under NASDAQ Listing Rule 5635(c)(4) as inducement material for employees entering employment with Rigel.
Rigel Pharmaceuticals Inc

NASDAQ:RIGL

RIGL Rankings

RIGL Latest News

RIGL Stock Data

302.24M
17.38M
2.84%
68.52%
8.28%
Biotechnology
Pharmaceutical Preparations
Link
United States
SOUTH SAN FRANCISCO